Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bonesupport, Audiocast, Q1'26

By Inderes4/22/2026, 8:00 AM
Bonesupport

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Torbjörn Sköld
00:01 - 11:50

Thank you. Operator. Welcome, everyone, to BONESUPPORT Q1 2026 Results call. My name is Torbjörn Sköld, CEO of BONESUPPORT. With me here today is our CFO, Håkan Johansson, and together we will use the next 25 minutes to guide you through the Q1 presentation and then open the line for questions. Before starting the presentation, I would like to draw your attention to the disclaimers covering any forward-looking statements we will make today. So, let's look at the financial and operational highlights of the quarter. Q1 was another strong quarter with solid execution across the business. Net sales came in at 324 million SEK, corresponding to a growth at constant exchange rates of 31% versus Q1 2025. Reported growth was 14%, showing that there was a continued strong currency impact on our figures for the quarter. Our adjusted operating result, excluding incentive program effects, was 85 million, corresponding to an adjusted operating margin of 26%. Reported operating result was 72 million. We saw another quarter of solid cash generation, with operating cash flows reaching 75 million SEK, resulting in a cash position of 455 million SEK at quarter end. We continue to see strong traction for CERAMENT G in the US, with sales reaching 222 million for the quarter, compared with 178 million SEK in Q1 2025. The sequential CERAMENT G growth quarter over quarter of 2.6 million USD was the strongest ever in Europe and the rest of the world. We saw strong momentum across all markets with growth of 16% at constant exchange rates compared to a very strong Q1 2025. It was also notable that our first segment sales in India were achieved during the quarter. During the quarter, the regulatory process for CERAMENT V progressed according to plan within the framework of the De Novo process as communicated in early December. The FDA submission for CERAMENT V was transferred from a 510(k) pathway to the De Novo process in close dialogue with the FDA. If granted market authorization, CERAMENT V will constitute an entirely new product category like CERAMENT G did in 2022. Just as in the review of the De Novo application for CERAMENT G, both CDER, FDA's Center for Drug Evaluation and Research, and CDRH, Center for Devices and Radiological Health, are involved, and the lead review team, which falls under CDRH, remains the same as during the 510(k) process. BONESUPPORT has received questions within the scope of the De Novo process and is working purposefully to address the requested details and clarifications. Responses are to be submitted no later than the end of August. We are progressing with the early stage launch of CERAMENT BVF for Spine in the US, in line with plan. The introduction in Spine is an important step as we continue expanding our portfolio of indications and applications. Now let's move on to the sales development. Next slide please. The chart shows total last 12 months reported sales in Swedish krona by quarter since 2019. In stacked bars per region and product category. As you can see, the launch momentum for CERAMENT G in the US is exceptionally strong, given that we keep bringing new, strong clinical studies and opening up new market segments and new indications. A product like CERAMENT G will remain in launch phase for many years to come. However, throughout 2025 and in the first quarter of 2026, we have seen strong influence from the US dollar to Swedish Krona depreciation, which influences the optics of the graph but not the in-market performance, as you will see in Håkan's slides later in the presentation. Last 12 months growth in Q1 of 22% in the graph corresponds to an even stronger 35% at constant exchange rates. So the quarter-over-quarter slowdown in the Last Twelve Months sales is mostly due to strong currency impact. US CERAMENT BVF last 12 months sales were flat year over year at constant exchange rate. In total, the antibiotic eluting segment grew by 48% over the last 12 months in the quarter at constant exchange rates. Next slide please. In the US, sales amounted to $267 million, representing growth of 35% at constant exchange rates. We continue to experience strong growth of CERAMENT G, driven by both increased access to new accounts and new surgeons, as well as wider adoption among existing users. We see growth from all three prioritized platforms: foot and ankle, trauma, and arthroplasty. At the American Academy of Orthopaedic Surgeons Congress in March, presentations and discussions confirmed the strong clinical interest in the CERAMENT V platform and the commercial momentum in the US. Dialogues with surgeons and distributors show that CERAMENT G is perceived as a clinically relevant and practically useful solution in a broad range of procedures, where there is a need for combined bone healing and effective infection control. During the quarter, clinical evidence was further strengthened through the publication of positive data for CERAMENT G. In February, the first US clinical pilot study in trauma was published describing surgical technique and treatment results with CERAMENT G. The study, conducted at a US level one trauma center and published in OTA International, provides practical and real-world insights into how CERAMENT G is used in clinical practice in the US. Additional support was added in March through the first US clinical case series, focused on infection prevention in open fractures, by demonstrating how local antibiotic release can be combined with existing surgical techniques. The study highlights the clinical relevance CERAMENT G has within a segment with a high risk of infection, despite the limited scope of the studies. They are of great practical importance as they provide concrete support regarding application techniques and expected outcomes for surgeons introducing CERAMENT G into their daily clinical practice. As part of our ambition to modernize an outdated standard of care in the US, we have successfully opened one market segment after another, starting with foot and ankle, followed by trauma and now moving into arthroplasty. Interest continues to grow for CERAMENT G in Revision Arthroplasty and Periprosthetic joint infections, two areas where the clinical needs remain substantial and where the evidence supporting our antibiotic-eluting technology has resonated strongly with surgeons. We have built a solid foundation for our Spine strategy over the past quarters by establishing distributor coverage and preparing the market. In Q1, we continued the early stage launch of CERAMENT BVF in spinal procedures, with distributors now actively engaging spine surgeons across both existing and new partnerships. The surge in access and early stages of adoption in Spine follows the plan and indicates the strength and potential of this segment; as this is a new clinical segment for us, more clinical data is needed to support broader market penetration. Importantly, the performance of CERAMENT BVF in Spine will help confirm the value proposition for the CERAMENT V platform, which will pave the way for the future antibiotic eluting CERAMENT V at launch. We've made strong progress in evaluating and preparing the regulatory pathway, and we'll share more on the path forward at our Capital Markets Day this spring after Q1. The U.S. Centers for Medicare & Medicaid Services (CMS) announced a proposed ruling. Full-year 2027 Inpatient Prospective Payment System (IPPS), including changes that improve payments for the use of CERAMENT G in the treatment of complex orthopedic infections such as periprosthetic joint infection, fracture-related infections, and diabetes-related bone infection. In parallel, CMS proposes the introduction of more specific procedure and identification codes for CERAMENT G and CERAMENT V, consistent with the company's Submission. CMS also proposes new technology add on payment NTAP reimbursement for CERAMENT V effective October 1st, 2026, provided that FDA grants the company's De Novo application by April 30th, 2026. If FDA approval is obtained at a later point in time. We plan to submit a new application with a potential for additional payment from October 1st, 2027, although this is a proposed ruling. This is very positive for BONESUPPORT as it validates the uniqueness and value it brings and reduces the potential financial barriers for using CERAMENT G in daily clinical practice. The company intends to submit additional clarifications to the CMS during the ongoing 60-day public comment period. A final decision from CMS is expected in late summer 2026. Now let's turn to Europe. Next slide please. Sales in EUROW came in at 57 million, representing 16% growth at constant exchange rates. This is compared to Q1 2025 where we saw strong growth in EUROW. Thus a very strong comparative quarter. We saw strong development across our three market structures: direct, hybrid, and distributor markets. UK continued the recovery we saw during the fourth quarter of 2025. Our investments in hybrid markets developed well. Underlying clear continued potential ahead in our distributor markets. CERAMENT V was launched as planned in India with a focus on the private market. We note some uncertainty in the Middle East, where geopolitical unrest is affecting market presence and logistics in the short term. Now, I'll leave the deep dive into the numbers to the next presenter.

Håkan Johansson
11:50 - 18:22

Thank you Torbjörn. Net sales improved from 284 to 324 million, equalling a reported sales growth of 14% or 31% in constant exchange rates. Torbjörn has already spoken about the solid performance, especially in the US, and the major drivers behind the sales growth. But as the significant US dollar exchange rate movements, compared with the first quarter last year, somewhat hide a continuous strong trajectory in the US. I would like to share the US sales performance in US dollars. CERAMENT G is the growth driver in the US, and this slide shows the quarterly CERAMENT G sales in the US in US dollars. We can note an all-time high sequential growth, which resulted in accelerated sales growth per week. The contribution from the US segment improved by $25.5 million versus Q1 2025, and amounted to $122.7 million. The improved contribution relates to increased sales, partially offset by increased costs. Selling and marketing expenses during the quarter amounted to $128.4 million, compared with $121.6 million previous year, of which sales commissions to distributors and fees amounted to $85.1 million, compared with $78.8 million the same quarter last year. From the graph at the bottom of the screen, showing net sales as bars and gross margin as the orange marker, it can be noted that the gross margin remains stable and strong at 94.5%, with a minor decline in the period following a gradual impact from tariffs in Europe and rest of the world. A contribution of 12.7 million was reported, compared with 15.4 million the previous year. Selling and marketing expenses increased by 6 million, mainly related to the previously communicated commercial investments in the so-called Euro booster programme, as shown in the lower graph and the orange marker. A minor improvement in gross margin can be noted, mainly impacted by market mix. Selling expenses, excluding sales commission and fees, increased by 11.6 million. Following commercial investments in both the US and Europe, but also related to high intensity in terms of marketing activities, research and development remained at a stable level and focused on the execution of strategic initiatives such as the application studies and Spine procedures and the market authorization submissions for CERAMENT V in the US. And finally, administrative expenses, excluding the effect from the long-term incentive programs, remaining stable with an increase of 1.4 million in the period. The adjusted operating result amounted to 84.9 million, with only minor currency effects impacting. I will come back to this on a later slide. The newly introduced tariffs in the United States had variable impact on costs in the quarter. The full effect of a 15% tariff will equal an impact of 0.8 percentage points on US gross margins, and this will come gradually, with full effect later in 26. The difference between adjusted and reported operating result is costs. Regarding our long-term incentive programs, amounting to an expense of 12.8 million in the quarter, compared with an expense of 10 million in the previous year, as you could see on the previous slides. The increase in expense included 1.6 million related to the long-term incentive program approved by the AGM in May 2025, which was included in the accounts for the first time this quarter. Operating cash flow was strong in the period, partially supported by inflow of customer payments deferred from December to after the holiday season. During the period, the Swedish krona has experienced volatility against the US dollar, with a minor weakening towards the end of the period and with only minor exchange gains and losses reported as other operating income and expenses. The graph on this slide shows, with the grey bars, how the relationship between the US dollar closing rate and the Swedish krona has varied over time. This is read out on the right Y-axis. The blue dotted line, read out on the left Y-axis, shows the adjusted operating result. The adjusted operating result, excluding translation exchange effects, is the orange line and gives a more comparable view on the underlying trend in operating results. In the table below the graph, you can see that the FX adjusted operating margin was 25.5% in the period, compared with 22.6% in the same quarter last year. In the shorter term, the operating margin is impacted by the commercial investments made in both EUROW and in the US. A gradual return to improvement in operating margin is expected as these investments are assumed to have positive impact on future sales growth potential. The relation between the US dollar and Swedish krona has been stabilizing over the last four quarters, which becomes visible when comparing the adjusted operating result, including and excluding translation exchange effects on a rolling 12-month basis; and, when observing the reported figures in Q1 this year, it is noticeable that the difference between including and excluding translation exchange effects is becoming narrower, following a more stable relation to the US dollar. The strengthening of the Swedish krona over time impacts both net sales and operating results, as visible in the graph. A solid cash conversion has been reported continuously since the third quarter of 2024, with an average cash conversion of 81% visible as the dotted line in this graph. Q1 this year reported ahead of the average, mainly due to the previously mentioned timing effects from customer payments. And with this, I hand back to you, Torbjörn.

Torbjörn Sköld
18:23 - 19:17

Thank you. Jochen. So to summarize, Q1 2026 sales grew by 31% at constant exchange rates, reflecting steady and consistent progress. Highlights were sequential CERAMENT G growth in US of 2.6 million USD. EUROW growth versus a strong prior year of 16% at constant exchange rates and record strong cash flow of 75 million SEK, underscoring the strength of the business and its scalability. I'm convinced that the most exciting part of our journey in BONESUPPORT still lies ahead of us, and I aim to provide a clear view of what that journey will look like. We will host a Capital Markets Day in Stockholm on the 26th of May this year, which you are of course, all welcome to join. Now with that, we're opening the line for questions. Thank you.

Operator
19:18 - 19:34

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Kristoffer Lilleberg from DNB Carnegie. Please go ahead.

Kristoffer Lilleberg
19:36 - 20:53

I think you have three questions. First, on the increased selling expenses here in the quarter, would you say that you have reached a new level now, or should we expect them to continue to increase sequentially? And related to that, how you think about operational leverage here going forward. I'll note this, underlying EBIT has been more flat here sequentially. So would you expect it to pick up again here coming quarters? My second question relates to the sales commission in the US. That seems to be down as a percent of sales. I notice it is flat sequentially despite the higher sales. If you could explain that. I know there's other variable costs included in that maybe as well. And then, when it comes to the De Novo process for CERAMENT V in the US. If you could explain a little bit what type of questions FDA has and why you sound so confident that the product will eventually be approved and the risk of not receiving an approval. Thank you.

Håkan Johansson
20:54 - 23:06

Thank you. Kristoffer and I will start answering the first two questions, and then I will hand over to Torbjörn to answer the question on the De Novo process. So let's start with the increased selling expenses. And again, as we have also previously communicated, we will continue to make gradual commercial investments if we believe that this is beneficial to sales growth. And on that theme, we have been both investing in the so-called EUROW booster program, but we have also continued to strengthen our US organization in terms of medical education activities, national accounts management, and also more sales related functions,etc. To continue supporting the growth and the aspirations in the three main segments in the US. So again, a gradual increase can be expected. But as we also mentioned in the call, we expect this to have beneficial impact also on sales and sales growth going forward. And we also expect that to lead to a gradual improvement in operating margins when it comes to sales commissioning fees. I'm glad that you noted that there is a reduction in the percentage to sales in Q1, and there is one main driver in this. And that is an activity that we've been running in the US focused on balance sheet and process efficiency. It's been a program to move customers from paying with credit cards to pay electronically through our bank systems. And this is an activity that has resulted in a lower cost for credit card fees. And that is sustainably moving the fees down by a percentage point. So that's the main driver for the reductions. There are some other reductions in the quarter, but they are more seasonality driven than anything else. But the main impact comes from reduced credit card charges.

Kristoffer Lilleberg
23:08 - 23:12

And what did you say the impact was as a percentage of sales?

Håkan Johansson
23:12 - 23:15

It's a 1% saving.

Kristoffer Lilleberg
23:15 - 23:21

Okay. So this is a sustainable effect. Yes. Yes. Okay. Thank you.

Torbjörn Sköld
23:22 - 26:02

Okay. And then to the third question that you had around De Novo. So the way that we look at this and interpret this is, first of all, the De Novo process compared to a 510(k) process. It sets a higher bar, it sets a higher standard, that is not only a negative, it's actually also a positive, meaning that it strengthens the moat. What we also see is that the pattern we see from the FDA is very similar to the de novo process that we had for CERAMENT G. What I said on the call, and I think is also important to highlight, is that as part of the 510(k) process, the Department of the FDA that was involved was the CDRH. So the Center for Devices and Radiological Health, they were involved, they are still involved and they are still leading the audit as we move to a De Novo process. And as this product is a combination product. So it's a device with drug-eluting properties, then the CDER. So the Center for Drug Evaluation and Research is also involved. They're brought into the process. The questions that we have received are more of the nature of being explanatory and clarifying rather than anything else. The three areas, which are also fully expected and planned for, are in the areas of pre-clinical, clinical, and biocompatibility. Now we're working on these questions diligently, and we want to answer them in a disciplined and robust way to make sure that we properly inform, educate, if you will, the FDA, to understand what this technology does with CERAMENT V, what it already does with CERAMENT G, which is FDA approved. And also, CERAMENT V is a product that has been approved outside of the US for many, many years. It is used every day in patients. So with that, I feel comfortable that it's more of not so much an 'if'. If we get approval, it's more of when we get it. And having said that, we control what we can control, how FDA reacts and responds. That is outside of our control, but I feel comfortable that we're on the right path and we will get it to market. It's more a question of when.

Kristoffer Lilleberg
26:04 - 26:11

Could I ask, but just, it's not that they are requesting more data similar to what happened with CERAMENT G.

Torbjörn Sköld
26:12 - 26:18

So far, it's more explaining and more details of the existing data that we have already provided.

Kristoffer Lilleberg
26:20 - 26:21

Okay, great. Thank you.

Operator
26:25 - 26:29

The next question comes from Mathias from Seb. Please go ahead.

Mathias
26:32 - 27:04

Hi. Good morning. Thanks for taking my question. I have a few. So I think as you pointed out, the solid quarter over quarter sales growth for CERAMENT G in the US. So, could you just tell me if there is something non-recurring or extraordinarily supportive in the quarter, or if this is purely better penetration? And if so, what are the key contributors? You mentioned all of the areas. Anything to point out there. That's the first one.

Torbjörn Sköld
27:06 - 28:21

Okay. Boring answer. No, it's no one-timers. It's not non-recurring. It is more of the same that we've seen in the past. And the growth comes from all three segments: foot and ankle, trauma, and arthroplasty. And in absolute numbers, all three contribute positively. Of course, there's a lot of excitement internally and externally in our two newer segments. So trauma and arthroplasty, but all three segments contribute in a meaningful way in the quarter. When we look at existing and new accounts, it's very much the same trend that we saw in 2025 throughout the year. And also at the end of the year, meaning that we get meaningful growth from both existing accounts, increasing their adoption as well as we see meaningful growth coming from shifting from awareness to access with access on many different layers. Unfortunately, there's nothing more exciting than that. Matthias, to your first question.

Mathias
28:23 - 28:37

No thanks. That helps. My next one or follow-up in terms of working days, what is the same in Q1 and Q4? And what do you see here in the second quarter coming up?

Håkan Johansson
28:38 - 29:01

So it's correct. So it's on the same level as Q4. So it's 61 days. And the number of workdays is increasing in Q2. And the effects are starting with Easter holiday. And at the risk of misremembering, I believe it is 63 days in Q2.

Mathias
29:04 - 29:26

Thank you. I have a few more in terms of CMS. Proposing changes that improve the payment for using CERAMENT G, as you also mentioned in the presentation here. Can we say anything on magnitudes? And can you refresh us just how important the CMS exposure is for BONESUPPORT and so on?

Torbjörn Sköld
29:28 - 33:08

No. So, first of all, it is a proposed ruling. So it has not been approved. It's not been decided on yet. Number two, this full year 2027 IPS document is fully public. Number two, this full year 27 IPS document is fully public. So all of you can go ahead and read it. Knock yourself out. It's 1600 pages of text, a very small portion of that, but still quite a bit of text related to CERAMENT V, as it's complex with many different codes and several indications impacted. And when we look at it, and when we also have. Advisors looking at it, there is also a bit of interpretation in it. So we don't want to draw too many conclusions and too many specific conclusions yet. However, at a total and high level, it is very, very positive. And pretty much everything that we requested in our submission pretty much went through. We have a couple of clarifications on how we should interpret it, but overall, it's very, very positive. There are many layers in this proposed rule. And I think some of them you can sort of peel out or take out separately. One is the proposed end cap for CERAMENT V. It's pretty standard. We would have been disappointed if we didn't get it. So that's one thing. The other thing is the extension of NTAP for CERAMENT G for open fractures. That is also sort of expected. And you can strip out what remains. So if we strip those out, and those are very positive for us, what remains is, in my mind, even more strategically important for BONESUPPORT because it highlights a couple of things. Number one, it highlights that CMS continues on the path to pay more for outcomes rather than activities. Why that is important for BONESUPPORT is that, yes, we have a very expensive product, but the whole value proposition with CERAMENT G is to avoid infections, avoid revision surgery, avoid readmissions. It is clear that, not only specifically for CERAMENT G, but generally within this proposed rule, CMS is moving in that direction. So that is very positive. And then you can see it in diabetic foot infection, fracture-related infection, and periprosthetic joint infection. CMS proposes to incentivize technologies like CERAMENT V and also, to a certain extent, almost use CERAMENT G as a trigger point for a higher reimbursement because CERAMENT V is very much linked to other cases that have higher complications and comorbidities. So, and I know you guys want a specific number. How much will sales go up? We cannot provide that. We don't know yet. It's complex material. We're analyzing it. But we're very, very pleased and satisfied with the proposed ruling. And look forward both to the clarifications that we expect in the next couple of weeks and also the ruling to come into effect later this year with full effect next year.

Mathias
33:10 - 33:45

No, but that's helpful. Thank you very much. Lastly, I have a follow up to Christopher's question regarding CERAMENT V in the US. So if I catch this correctly, the 150 day review period will pause and it will resume when you submit your answers or call it clarifications. So with this in mind, what kind of delay do you think we're looking at here in the process? Just a couple of months, or is August sort of a formal last date? It does not necessarily mean that BONESUPPORT will resubmit in August, I guess.

Torbjörn Sköld
33:47 - 35:11

So I'll answer number one. You're correct. You're correct in your first statement about the timing and the clock there. That's number one. Number two is knowing how the FDA will act and what they will do regarding CERAMENT G is impossible for us to guess. Whether it is a delay or not? It depends on who you ask. Now, what we want to do and want to make sure is that we answer the questions in a disciplined, robust way so that we get the approval in a way that we wanted to, not only as fast as possible, but in as robust a way as possible. So that's what we're doing. But again, you never know with the FDA. Now, the end-August timeline that we communicate, that's the formal deadline. We will use that if we feel that it is necessary and we feel that it is good for the process, if we feel that we can submit it faster than end August without risking the quality of the material and the outcome of the process. We will, of course do that. But end August is the latest formal deadline that we have.

Mathias
35:13 - 35:19

But it's still reasonable to expect it to be cleared 2026 with all of this in mind.

Torbjörn Sköld
35:20 - 35:38

You know, it's always difficult to guess what FDA does. I feel comfortable that we're on a good path. It's not so much a question if it could be in 26, that's my best guess. But, you know, if it needs to be extended to 2027, it's worth waiting for for sure if we put it that way.

Mathias
35:40 - 35:42

Okay. Thank you very much.

Operator
35:46 - 35:51

The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.

Sten Gustafson
35:53 - 36:16

Good morning and thank you. Just sorry for going back to this CERAMENT V. I'm not sure if I got it right here, but could you please confirm that you do not need to carry out any additional clinical studies in order to be able to answer the questions from FDA. Is that correct?

Torbjörn Sköld
36:17 - 36:21

That is our current hypothesis and our current assumptions. So yes, that's correct.

Sten Gustafson
36:23 - 36:55

Perfect. Thank you. My second question is regarding the sales split of CERAMENT G and CERAMENT V in Europe. Is it possible for you to see in how many cases you use both products at the same time? where there's a super broad infection, whether doctors use it in combination.

Torbjörn Sköld
36:56 - 37:00

So just so I understand the question, are you referring to? US?

Sten Gustafson
37:02 - 37:18

Yeah. In Europe, for example, where both products are approved and being used. CERAMENT G and CERAMENT V. Do you have a feeling for how many procedures doctors use both products at the same time?

Håkan Johansson
37:19 - 37:39

We know anecdotally that it happens, but we have no data-driven substantiation that we can lean on. But we know anecdotally that it happens, but it is not extensive in terms of using both.

Sten Gustafson
37:41 - 37:53

No, I get it. Excellent. Thank you. And regarding the split, do you have a feeling for that in terms of procedural usage?

Håkan Johansson
37:53 - 38:08

With some volatility. It's somewhere between a 25/75 and 20/80 split where some of the largest use is on CERAMENT G. So roughly 25, 75.

Sten Gustafson
38:09 - 38:22

Okay, perfect. Thank you. My last question is regarding Germany, and I'm not sure if I missed it in the report, but are there any comments on how Germany is developing for you?

Håkan Johansson
38:23 - 39:02

Germany is somewhat positive because it's stable. And what I mean with that is that it feels like it's trending on the same level as the previous quarter, meaning that we don't see a decline. And I think that's a good sign that, again, as we have commented, we're still focusing on Germany. We still have strong relations to German hospitals and German surgeons, etc. . And I think that for Q1, we're glad to see that the development is stabilizing.

Sten Gustafson
39:04 - 39:05

Perfect. Thank you very much.

Operator
39:09 - 39:13

The next question comes from Eric Cassel from Danske Bank. Please go ahead.

Kristoffer Lilleberg
39:15 - 39:17

Hello. Hi. Good morning.

Eric Cassel
39:17 - 39:55

I wanted to focus a bit on the trauma centers in the US, which you gave figures for in last quarter. I mean penetration rate was obviously quite high. But is it possible, now that they've conducted pilots, potentially up to a year ago, to discuss the current conversion rates from pilots to continued use? And then also if you can say anything on how high continued use is as of now, and how many of those are still in sort of an evaluation phase.

Torbjörn Sköld
39:56 - 41:43

Okay. Thank you Eric. We will not provide any numbers to answer your questions, but we can provide a bit more color. We can provide a bit more color on your question related to trauma in the US. So as I mentioned, we saw that all three segments contributed in a meaningful way for the quarter. That also includes trauma. So we see that the journey that we're on in trauma follows the plan and follows the expectations. I also said that there's a lot of excitement internally as well as externally around trauma and arthroplasty. That speaks to it. I think what creates internal and external excitement and helps us on this journey that you refer to are the two studies that we talked about earlier. I know that actually you quoted that those were not really meaningful studies. I would argue against that and say that they are very meaningful for us from a commercial perspective. And they get traction because it's a great way for us to talk about our product in a practical, evidence-based way. So we're seeing in trauma, there's continued excitement. We continue to move from awareness to adoption. Sorry, from awareness to access to adoption. So now we're becoming more in the access and adoption phase with many more years to come in trauma, partly supported by the evidence that we provided. But we don't really give on a quarterly basis any data that you're asking for. Eric.

Eric Cassel
41:45 - 42:26

Okay. That's fair enough. And then I also wanted to sort of repeat a question from Christopher and see if we can get a bit more detail on it. You said in the report that the commercial costs are going to peak this year. But is it possible to maybe quantify or frame it in a bit more detail, the implied cost ramp you're going to see this year and how that also transitions into 27, because it makes it sound like the incremental margins this year might be a bit worse than what we normally see. So I just want to make sure that we get the expectations right on this.

Håkan Johansson
42:27 - 43:55

It's a fair question, Eric. And again, as there has been a repeated theme from our side, we will, and I promise you, we will continue to do commercial investments if we believe that this will be beneficial for continued sales growth. And. And on that theme, we have the EUROW booster as we've communicated. I think it's more than a year ago and that the EUROW booster is adding 10 million SEK in incremental cost, and it will take at least 18 months until that program is returning some sales. That concerns the cost in the US. We have been gradually strengthening the organization. And we just look at current plans. That means that from the second half of last year and going into this year, we are adding ten heads into our US organization because we believe that this will be beneficial for the US sales growth that will create in the shorter term a reduced positive trend in terms of operating margin. But as we said on the call, we are strong in our view and believe that this will come back to continued gradual improvements in the operating margins.

Torbjörn Sköld
43:56 - 44:32

Absolutely. And on top of that, if we look at this case on a more of a couple of years basis, there's plenty of operational leverage in this business with what we're doing. We've taken quite substantial investments both in EUROW as well as in the US. So, if you take a longer-term perspective, there's no change in the potential of the operational leverage of this business. On the contrary, when we look at that internally and strategically in the longer-term horizon.

Eric Cassel
44:34 - 45:14

Okay. Thank you. And then I wanted to touch upon the US sales. That was, I guess, a soft point in this report. Previously you talked more about the CERAMENT V products perhaps becoming an add-on to CERAMENT G so that you get new accounts using CERAMENT G. And then they also start to use the product. Now it more looks like that there's cannibalization on the product. Have you changed what you're seeing for CERAMENT BVF and the longer-term implication of that? Or are you actually seeing any CERAMENT G accounts also picking up? BVF.

Håkan Johansson
45:15 - 46:26

So, I think that in the longer term, we stay firm with that view because, again, we continue to see that surgeons that have been bringing on new cases thanks to CERAMENT G are also using the BVF product for surgeries where there is none to very low infection risks. I think that what we've seen in the first quarter is in a way not negative for the longer term, because what we've seen, which somewhat explains some of the softer sales of CERAMENT BVF in the US, is that surgeons who have been traditional and solid CERAMENT G users. Users have converted and increased. Its use of CERAMENT G has increased. We believe that is positive, even though it may have a short-term impact on the sales. But again, our statistics show that somehow we are succeeding. With CERAMENT G as planned. It acts as a growth engine, bringing in new solutions. We also see that those surgeons are using BVF. So over time, we believe that BVF will first stabilize, but then we will see low single-digit annual growth coming back.

Eric Cassel
46:29 - 46:38

Okay. But on the timing of that now looks like it's cannibalization. Do you think that will continue or is this sort of a stable rate, do you think, for that product?

Håkan Johansson
46:38 - 46:54

I think it's too early to say because it was really visible this quarter in a stronger way than what we've seen. . So, Eric, let's come back to that question in Q2 and see if that trend remains.

Eric Cassel
46:57 - 47:26

Okay. Thank you. Just the last one, if I may. On the gross margin headwind from tariffs. I understand that as you're, of course, manufacturing the products with contract manufacturers, is it possible, in the medium term, to transfer production locally to the US to offset this, or is the relative cost in the US basically too high? So it wouldn't be enough of an offset to actually do that.

Håkan Johansson
47:27 - 47:55

From a purely practical point of view, that could be a consideration. But from a regulatory point of view, to move production is a very time-consuming and costly process. So we will continue to ask the US business to look at various options when it comes to manufacturing. But here and now, to offset tariffs. It's not a helpful strategy.

Eric Cassel
47:57 - 47:59

Okay. Fair enough. Thank you very much.

Operator
48:02 - 48:06

The next question comes from Oscar Bergman from Redeye. Please go ahead.

Oscar Bergman
48:08 - 48:27

Hello, everyone, and thank you for the very interesting report, as always. I have a few questions left. I think the first one, if you could just clarify the constant exchange rate growth for CERAMENT G in the US, I think it would be helpful.

Håkan Johansson
48:29 - 48:32

So explaining in terms of.

Oscar Bergman
48:36 - 48:41

The constant currency exchange growth for US CERAMENT G in Q1?

Håkan Johansson
48:42 - 49:12

So, again, as we showed in the graph, the sequential growth of CERAMENT G in the US was 2.6 million USD. And that is somehow what supports. Supporting the reported statements and numbers. So I'm sorry, it's not clear. Maybe it's too early in the morning for me. And so I think you have to clarify really what you're after, Oscar.

Oscar Bergman
49:15 - 49:41

Yeah, I was just thinking, maybe I'll have to check the report again. Those numbers. Maybe it was too early in the morning for me as well. I think we can just move on to the other question instead. Yeah. Our new CERAMENT BVF for Spine is still very early stage. And you don't report this separately, but could you just give some sort of ballpark figure or anything that helped me sort of decipher the sales contribution so far?

Torbjörn Sköld
49:42 - 51:45

No. So, the Spine BVF launch follows the plan, and just to remind everyone. But this is very important. It is that we take a very, very focused approach on Spine. Bvf. And we've said that from a revenue perspective, we will not have any material impact on the overall numbers, on the total or even on the BVF side. So, it's really small numbers for Spine. Bvf. And the reason for that is simply, we're not involved. Spine. We're not going after Spine to sell. Bvf. Our hypothesis on Spine is that it's a very attractive segment for us, offering a product that does the two things that CERAMENT does perfectly: healing bone and, in a very controlled, predictable way, eluting antibiotics. So, from a sales point of view, Spine BVF, I wouldn't put any material numbers in that if that's what you're going after. However, what is very positive to see in Spine is that our hypothesis and assumptions about that segment in terms of the strength of the value proposition is being confirmed in the quarter. So, but also just to manage expectations, to come with an antibiotic-eluting product into Spine is a couple of years out. We need the clinical evidence, we need the regulatory approval. So that still remains the same. So no change really, but Q1 in Spine with BVF confirmed at least what we see that we're on the right track and our assumptions and hypotheses so far remain valid.

Oscar Bergman
51:47 - 51:52

But can you share any numbers on, maybe, the number of customers that have tried out the product?

Torbjörn Sköld
51:55 - 52:33

No, we don't provide any specifics on that. But we have wanted to keep it low. And that's how we want it. And we're being very selective in which accounts we're going after. And, to be fair, we could have gone for more accounts if we wanted to and actively promoted it much more, but we want to keep it very strict, very disciplined, very controlled so that we do it in the right steps for the long-term case of CERAMENT V. Spine.

Oscar Bergman
52:34 - 52:46

And I guess it's a fair assumption that you are targeting customers where you already have some experience with CERAMENT G for extremities, or are you going for hospitals outside your current customer base.

Torbjörn Sköld
52:46 - 53:32

We're doing both, to be honest, because, again, it comes back to that you want the right surgeon, you want the right hospital that believes in our hypothesis of CERAMENT V in Spine, that believes and acknowledges the fact that infection is an issue, and that also believes and buys into the characteristics of CERAMENT V; sometimes they come in already existing partnerships with our independent sales reps in extremities. Sometimes, they come outside. So we're not insistent that they have to come from the existing distributors. So we see a combination of both.

Oscar Bergman
53:34 - 53:50

And I know you have a CMD in about a month's time. And I guess we'll hear more about the Spine segment there, but do you still expect it to be registered as a medical device and not having to go through a drug registration process?

Torbjörn Sköld
53:51 - 54:07

Yeah. Our approach here is that we're a medical device company. We want to remain a medical device company. Similar to what we've done with CERAMENT G and CERAMENT V. And that's also our plan and thinking on Spine.

Oscar Bergman
54:09 - 54:28

Okay. Okay. And then just maybe a final question. The launch in India. I'm very happy to hear that you have first sales there already, but I suspect that very small numbers still; can you give some words on the progress here and maybe what we should expect for the full year?

Torbjörn Sköld
54:29 - 55:57

Yeah. No. Um, absolutely. I sit here next to our CFO. He's super excited because we've not only launched but also sold it. We've actually done cash collection. So for once, he is in a good mood when it comes to India. So that's great. Which is positive. But you're absolutely right. It's just the start. And in Q1, it's small numbers, and it's going to be small numbers as it always is when we enter a new country. With India, it's very exciting for a couple of reasons. Meaning that if you look at the size of the total population, it's massive. We're not going after that. We're going after a niche segment of that population. So private pay and closely managed with private hospital chains where we have good collaboration and good trust. But even in our smallest estimates, the segment that we're entering corresponds to a sizable country in Europe with margins that are similar to distributor margins in Europe. So that's why we are excited. But it's early days. It takes time, but so far very pleased with what the team has done there and the progress that we've seen. But again, small numbers in Q1. And hopefully we'll work to make those numbers grow fast in a couple of years.

Oscar Bergman
55:59 - 56:02

Okay. Well, thank you very much. I'll see you at the CMD. Thank you.

Torbjörn Sköld
56:03 - 56:04

Thank you Oscar.

Operator
56:05 - 56:13

There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Torbjörn Sköld
56:17 - 56:45

Okay, we have a couple of minutes left, and we also have a couple of questions on the chat. And then we'll just quickly read through one question, and I'll leave this to Hawken. So I'll read Håkan and then you'll prepare. So Håkan, could you please help us on the R&D spend for 2026? Should we expect a similar ratio versus sales as seen in Q1 and 2025?

Håkan Johansson
56:45 - 57:23

So again, I think that what we've seen is a very stable run rate in the last four quarters. And I think there's a good baseline to start from; however, the uncertainty that we have is about pending the discussions with the FDA and the regulatory pathway to get an antibiotic-eluting product approved for Spine. And we believe that it will include and involve clinical studies and the absolute cost levels. And the timing of these costs remains to be clarified. And that will add to the run rate.

Torbjörn Sköld
57:24 - 57:47

Okay. Another question we have is around dividends and capital allocation. And I'm going to read it and then you will answer it. So why do you not consider a dividend appropriate at this time? What do you intend to do with the assets and the cash position of nearly 500 million?

Håkan Johansson
57:47 - 58:27

Well, it's a good question. And again, some of it is good to have a solid underlying cash flow because that builds also confidence in the business for any future investments, etc. . But also saying that we understand and we see that we are generating more cash than the business needs in the short to mid-term. And there is also a good reason why the board proposed to the AGM, the upcoming AGM in early May, to get a mandate to buy back shares in the market as one way to allocate the funds that the business is generating.

Torbjörn Sköld
58:28 - 60:20

Okay. And then we have another question related to CERAMENT V on the chat. And it goes like this. Do you expect that you will reply to FDA's questions regarding CERAMENT V before summer? So what we've said is that the deadline we have is end August, and we will reply to the FDA questions before end August. So we confirm what we already said. And then I believe there's one last question on the chat and it relates to the Solorio study and it says, when will the full report of the Solorio study be fully published? Or won't it be? So, again, we don't manage the submission to the scientific journal. This is done by the lead authors. But we have good reasons to believe that the Solorio study will be published in the near term, exactly when and in exactly which journal remains to be seen. But we have good reasons to believe that it will be published as per plan. And we also have. We believe that it will confirm this paradigm shift that we see and hear about, related to using systemic antibiotics versus local antibiotics. So we feel we have a good and positive outlook on this study. So, hope to see something there in the short to medium term. I believe that is it.

Håkan Johansson
60:20 - 60:22

That concludes.

Torbjörn Sköld
60:22 - 60:33

So with that, right on time. Thank you all for dialing in. And again, warm welcome to the Capital Markets Day in Stockholm on May 26th. Thank you very much.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…